廖宇宁，男，博士，副研究员。1991年5月出生，2013年毕业于广州医科大学护理学专业，同年9月至2019年6月在广州医科大学硕博连读，获临床病理学与病理生理学博士学位。2019年8月入职广州医科大学基础医学院病理生理学教研室/广东省蛋白质修饰与降解重点实验室，2020年认定为广州医科大学“南山学者”骨干人才，博士生导师。长期致力于蛋白质修饰与肿瘤发生发展方面的研究，近年来发表SCI论文30余篇，其中以第一/通讯作者（包括共同）发表论文10余篇，代表性论文发表在Advanced Science, Cell Discovery, Oncogene, Theranostics, Journal of Experimental & Clinical Cancer Research,和Cancer Letters等国际权威杂志上。在读研究生期间曾获得两次国家奖学金、广东省优秀研究生、广东省大学生年度人物（学术科研类）提名奖、广州医科大学优秀毕业生、广州医科大学优秀博士论文等奖励。主持国家自然科学基金、广东省教育厅和广州市科技局等科研项目。

主要论文发表情况：

1. Liao Y#*, Liu Y#, Yu C#, Lei Q, Cheng J, Kong W, Yu Y, Zhuang X, Sun W, Yin S, Cai G*, Huang H*. HSP90β Impedes STUB1-Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma. Advanced Science, Sep;10(27):e2302025. (IF 15.1, 中科院1区)

2. Liu Y#, Kong W#, Yu C#, Shao Z, Lei Q, Deng Y, Cai G, Zhuang X, Sun W, Wu S, Wang R, Chen X, Chen G*, Huang H*, Liao Y*. SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16. Acta Pharmacologica Sinica, 2023 Apr;44(4):853-864. (IF 8.2, 中科院1区)

3. Liao Y#, Sun W#, Shao Z#, Liu Y, Zhong X, Deng Y, Liu F, Huang H*, Liu J*. A SIX1 degradation inducer blocks excessive proliferation of prostate cancer. International Journal of Biological Sciences, 2022 Mar 14; 18(6): 2439-2451. (IF 9.2, 中科院2区)

4. Liao Y#, Shao Z#, Liu Y#, Xia X, Deng Y, Yu C, Sun W, Kong W, He X, Liu F, Guo Z, Chen G, Tang D, Gan H*, Liu J*, Huang H*. USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. Journal of Experimental & Clinical Cancer Research, 2021 Jun 21;40(1):201. (IF 11.3, 中科院1区)

5. Liao Y#, Liu Y#, Shao Z#, Xia X, Deng Y, Cai J, Yao L, He J, Yu C, Hu T, Sun W, Liu F, Tang D, Liu J*, Huang H*. A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance. Oncogene, 2021 Jun 2. (IF 8, 中科院1区)

6. Liao Y#, Liu Y#, Xia X#, Shao Z, Huang C, He J, Jiang L, Tang D, Liu J*, Huang H*. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. Theranostics, 2020 Feb 10; 10(8):3366-3381. (IF 12.4, 中科院1区)

7. Liao Y#, Liu N#, Xia X, Guo Z, Li Y, Jiang L, Zhou R, Tang D, Huang H*, Liu J*. USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia. Cell Discovery, 2019 Apr 30;5:24. (IF 33.5, 中科院1区)

8. Liao Y#, Guo Z#, Xia X#, Liu Y, Huang C, Jiang L, Wang X, Liu J*, Huang H*. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer. Journal of Experimental & Clinical Cancer Research, 2019 Apr 11;38(1):157. (IF 11.3, 中科院1区)

9. Liao Y#, Xia X#, Liu N#, Cai J, Guo Z, Li Y, Jiang L, Dou Q, Tang D, Huang H*, Liu J*. Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. Oncogene, 2018 Apr;37(14):1896-1910. (IF 8, 中科院1区)

10. Liao Y#, Liu N, Hua X, Cai J, Xia X, Wang X, Huang H*, Liu J*. Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor. Cell Death & Disease, 2017 Feb 2;8(2):e2585. (IF 9, 中科院1区)

11. Liu Y#, Yu C#, Shao Z, Xia X, Hu T, Kong W, He X, Sun W, Deng Y, Liao Y*, Huang H*. Selective degradation of AR-V7 to overcome castration resistance of prostate cancer. Cell Death & Disease. 2021 Sep 21;12(10):857. (IF 9, 中科院1区)

12. Xia X#, Liao Y#, Huang C#, Liu Y, He J, Shao Z, Jiang L, Dou QP, Liu J*, Huang H*. Deubiquitination and stabilization of estrogen receptor α by ubiquitin-specific protease 7 promotes breast tumorigenesis. Cancer Letters, 2019 Sep 10;465:118-128.

(IF 9.7, 中科院1区)

13. Xia X#, Liao Y#, Guo Z, Li Y, Jiang L, Zhang F, Huang C, Liu Y, Wang X, Liu N, Liu J*, Huang H*. Targeting proteasome associated deubiquitinases as a novel strategy for the treatment of estrogen receptor positive breast cancer. Oncogenesis, 2018 Sep 24;7(9):75. (IF 6.2, 中科院1区)

注：#代表第一作者，*代表通讯作者

主持的科研项目：

(1) USP1-UAF1复合体调控RPS16的泛素化降解促进肝癌恶性进展，国家自然科学基金委员会，82002481，24万元，在研，主持；

(2) 蛋白质修饰与肿瘤，广州医科大学优青成长项目，2023/01-2024/12，100 万元，在研，主持；

(3) 去泛素化酶USP1调控肝癌细胞生长和侵袭转移的分子机制研究，广州市科技局，202102020931，5万元，结题，主持；

(4) 核糖体蛋白降解调控在肝癌治疗中的作用及其分子机制研究，广东省教育厅，2019KQNCX113，2.5万元，结题，主持；

(5) SIX1调控CDK1蛋白降解促进肝癌细胞的索拉菲尼抵抗，广州医科大学附属第六医院，202011-304，20万元，结题，主持。